• রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন
Indications:
LINATAB 5 is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It may be used as monotherapy or in combination with other antidiabetic drugs such as metformin, sulfonylureas, or insulin.
Pharmacology:
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases the levels of incretin hormones, which help to regulate blood glucose by increasing insulin release and decreasing glucagon secretion in a glucose-dependent manner.
Dosage:
The recommended dose is 5 mg once daily. No dose adjustment is required for patients with renal or hepatic impairment.
Administration:
Should be taken orally, with or without food. Taken once daily at the same time each day for optimal effect.
Interaction:
Linagliptin has a low potential for drug interactions. However, caution should be taken when used with strong CYP3A4 or P-gp inducers like rifampin. When combined with insulin or sulfonylureas, the risk of hypoglycemia may increase.
Contraindications:
Contraindicated in patients with hypersensitivity to Linagliptin or any component of the formulation. Not for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
Side Effects:
Generally well tolerated. Possible side effects include nasopharyngitis, headache, cough, joint pain, and rarely pancreatitis or allergic reactions like angioedema.
Pregnancy & Lactation:
Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution should be exercised when administered to breastfeeding women.
Precautions & Warnings:
Monitor blood sugar levels regularly. Use cautiously in patients with a history of pancreatitis. Not a substitute for insulin in insulin-dependent patients. Advise lifestyle modifications along with medication.
Therapeutic Class:
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Storage Conditions:
Store below 30°C in a cool and dry place. Protect from light and moisture. Keep out of reach of children.